

8 April 2024

## Annual General Meeting Date

Singapore-founded regenerative medicine company **Osteopore Limited (ASX:OSX or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held on Thursday, 30 May 2024.

An item of business at the AGM will be the re-election and appointment of directors. In accordance with clause 7.5 of the Company's Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Thursday, 18 April 2024.

Any nominations must be received at the Company's registered office no later than 5:00pm (WST) on Thursday, 18 April 2024.

### ENDS

*This announcement dated 8 April 2024 has been authorised for release to the ASX by the Company Secretary of Osteopore Limited.*

For more information, please contact:

**Dr. Yujing Lim**

CEO & CTO

Osteopore Limited

E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)

**Isaac Stewart**

Media & Investor Relations

Cannings Purple

E: [istewart@canningspurple.com.au](mailto:istewart@canningspurple.com.au)

### About Osteopore Limited

Osteopore Limited is a Singapore-founded regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The Company seeks to commercialise products that stimulate natural bone healing across multiple segments.

Osteopore creates patented scaffolds using 3D-printed biomimetic and bioresorbable materials to guide and nurture bone-forming cells.



Through our proprietary manufacturing process – which uses a naturally dissolving polymer – our patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants.

**Forward-Looking Statements**

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

